Martin David Harp

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.

At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.

At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease

At ARVO 2025, in Salt Lake City, Utah, Yuhua Zhang, PhD, talked about his presentation on in vivo imaging of retinal pigment epithelium metabolic function in age-related macular degeneration

At ARVO 2025, in Salt Lake City, Utah, Patipol Tiyajamorn, talked about his poster on using graph neural networks to identify fast glaucoma progressors solely using optic nerve head morphology at a single time point

At ARVO 2025, in Salt Lake City, Utah, Anisha Kasi talked about her presentation on how her team used the TriNetX database, a large database of over 150 million patients worldwide, to validate the connection between hidradenitis suppurativa and inflammatory eye conditions.

At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

At ARVO 2025, in Salt Lake City, Utah, Noemi Guemes-Villahoz, MD, PhD, talked about 12-month results of vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses.

At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of Complement Factor H (CFH), a major genetic risk factor for AMD, and chronic oxidative stress affect the lipid profile of retinal pigment epithelial (RPE) cells.

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

At ARVO 2025, in Salt Lake City, Utah, Danielle Gauthier talked about her poster on autosomal dominant Alzheimer disease in relation to optic nerve head drusen.

At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its potential as a leading therapy.

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer disease and diabetic macular edema (DME).

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

Christina Prescott, MD, talks about the rate of recurrence of stromal keratitis in the Zoster Eye Disease Study, both in the placebo and in the treatment group.

Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.